734 results about "Phenacyl" patented technology

The present invention relates to a pharmaceutical composition comprising primarily amorphous 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester.

New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, at least one of R2 and R3 being other than hydrogen; R4 is a carboxylic acid amide (CONR′R″) or an acylsulphonamide (CONHSO2R′) derivative, or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof; or when n is equal to or greater than one, R4 may be a heteroaromatic moiety which may be substituted or unsubstituted, or an amine (NR′R″). R5 is hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (wherein R5=H). In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T3 regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.

The invention relates to a dental composition havinga) compound (A) with the following features:only one backbone unit (U) with 6 to 20 carbon atoms, at least 6 carbon atoms thereof forming an aromatic or an aliphatic cyclic moiety, the remaining carbon atoms either being part of substituents pending from the cyclic moiety or being part of bridging groups to spacer units, wherein one or more of the remaining carbon atoms can be replaced by an oxygen atom, the backbone unit not comprising a bisphenol structure,one or two spacer unit(s) (S) being connected to the backbone unit (U) via an ether linkage, at least one spacer unit (S) having a —CH2-CH2-CH2-CH2-O-CH2-CH(Q)-OG chain or a —CH2-CH(OG)-CH2-OM residue or a mixture of these two types of spacers within one spacer unit,with G having at least one group selected from acroyl, methacroyl, acetyl, benzoyl, and combinations thereof, M having at least one aryl group, and combinations thereof, Q having at least one group selected from hydrogen, methyl, phenyl, phenoxymethyl, and combinations thereof,b) filler (B) and c) initiator (C).

An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).

Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazineits salts and solvates thereof are herein set forth, as are pharmaceutical compositions comprising the crystalline form(s), as well of methods of using the crystalline form(s) in the treatment of HIV and / or AIDS, and methods for obtaining such crystalline form(s).

In the method of the present invention a plastic article (e.g., a molded article of thermoplastic polycarbonate) is immersed at least partially in a dye bath which includes one or more dyes, water, at least one carrier, and at least one diol. The dye bath contains: (i) at least one dye (e.g., a static and / or photochromic dye); (ii) water; (iii) at least one carrier represented by the following general formula I,R—O—(CH2)n—OHIwherein R is a radical selected from linear or branched C1–C18 alkyl, benzyl, benzoyl and phenyl, and n is 2 or 3; and (iv) a diol selected from at least one of linear or branched C2–C20 aliphatic diols, poly(C2–C4 alkylene glycol), cycloaliphatic diols having from 5 to 8 carbon atoms in the cyclic ring, monocyclic aromatic diols, bisphenols and hydrogenated bisphenols. In an embodiment of the present invention, the carrier is ethyleneglycol butyl ether, and the diol is diethylene glycol. The present invention also relates to a method of separating the dye from the water, carrier and diol components of the dye bath, by contacting the dye bath with particulate activated carbon.

The invention is to provide a weeding combination with a wide weed control spectrum, high activity and lasting effect. Active principles of the weeding combination provided by the invention are Alpha and Beta. Alpha is a compound or a salt thereof expressed by the formula (I); in the formula, R is a hydrogen atom or -COCH2OCH3. Beta is at least one compound selected from: at least one sulfonylurea compound selected from (B1.1) Bensulfuron-Methyl, (B1.2) azimsulfuron and so on; (B2.1) pyriminobac-methyl; (B3.1) an acetamide compound such as Pretilachlor; at least one benzoyl compound selected from (B4.1) benzobicylon, (B4.2) mesotrione and so on; (B5.1) a simetryne and so on.

The invention relates to novel substituted benzoylcyclohexanediones of the general formula (I), in whichm, n, A, R1, R2, R3, R4 and Z are each as defined in the description,and also to processes for their preparation and to their use as herbicides.